⚠ Medical and Legal Disclaimer — CKD Dietary Safety Critical

This document is NOT medical advice. CKD requires specialist nephrologist management. Do NOT modify potassium or phosphorus dietary restrictions, stop medications, or alter dialysis schedules without specialist supervision. Dietary errors (hyperkalemia, hyperphosphatemia) can be life-threatening in Stage 3-4 CKD. All protocols are adjunctive to specialist CKD management. Not FDA approved. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Table of Contents

Abstract I. Scale and the TGF-β1 Opportunity II. The Coherence Model of CKD III. The 15-Modality Protocol IV. Fluid and Device Platform
V. Condition-Specific Modifications VI. Falsifiable Predictions VII. Objections and Discussion References
Abstract

Overview — Direct Renal Evidence for the TGF-β1 Framework

Chronic kidney disease affects approximately 850 million people worldwide — 10% of adults globally. No FDA-approved therapy reverses established glomerulosclerosis or regenerates lost nephrons. SGLT2 inhibitors (DAPA-CKD, EMPA-REG) slow progression significantly — but they do not reverse fibrosis.

Direct Renal Evidence — Strongest in the Cross-Disease Framework
Chen 2019: 850 nm PBM Reduces Renal Fibrosis via TGF-β1 Smad2/3 in Diabetic Nephropathy
Chen et al. (2019, Lasers in Medical Science) demonstrated that 850 nm photobiomodulation reduces renal fibrosis in diabetic nephropathy specifically through TGF-β1 Smad2/3 pathway suppression. Wang et al. (2020) confirmed this in renal ischemia-reperfusion. This is not an extrapolation from scleroderma skin or GCA vessel walls — it is direct kidney evidence. CKD is therefore the strongest direct-evidence case in the Christos™ TGF-β1 cross-disease anti-fibrotic framework.
SGLT2 Inhibitor Synergy
Designed to Work With DAPA-CKD and EMPA-REG Therapy — Not Instead of It
SGLT2 inhibitors provide glomerular hemodynamic protection (tubuloglomerular feedback restoration, proximal tubule oxygen demand reduction, anti-inflammatory effect, partial TGF-β1 reduction). The Christos™ protocol targets the fibrotic and inflammatory dimensions SGLT2 inhibitors do not reach: established interstitial fibrosis reversal through 528 Hz PBM + RenalFlux astragalus + curcumin + alpha-lipoic acid; renal vascular coherence through HBOT and PEMF; systemic anti-oxidation through NAC and quercetin senolytic action. Prediction CKD-4 tests additive GFR benefit on top of SGLT2 inhibitors.

The protocol introduces Christos™ RenalFlux (a CKD-specific oral coherence fluid with strict potassium/phosphorus restrictions), the Renal Coherence Chamber (PEMF + bilateral posterior renal PBM + Solfeggio acoustic), and bilateral Renal Resonator Patches. 13 falsifiable predictions provided. Proprietary specifications available under NDA.

Section I

Scale, the SGLT2 Revolution, and the TGF-β1 Opportunity

1.1 Clinical Landscape

ParameterValue
Global prevalence~850 million; ~10% of adults worldwide; rising annually
Primary causesDiabetic nephropathy (40-45%); hypertensive nephrosclerosis (25-30%); glomerulonephritis; ADPKD; other
Stage 3b-4 to ESRD progression~10-15% per year in Stage 4; ~1-2% per year in Stage 3
Standard therapy highlightsACEi/ARBs (RAAS); SGLT2 inhibitors (FDA-approved CKD 2021-2023); BP control target < 130/80; dietary restriction
What standard therapy cannot doReverse glomerulosclerosis; regenerate lost nephrons; restore GFR to pre-CKD levels in Stage 3-4

1.2 What SGLT2 Inhibitors Do — and Don't Do

SGLT2 MechanismChristos™ Coherence Complement
Tubuloglomerular feedback restoration (reduces glomerular hyperfiltration)HBOT provides additional glomerular oxygenation through different mechanism
Proximal tubule oxygen demand reductionPBM 850 nm restores tubular mitochondrial function through cytochrome c oxidase activation
Anti-inflammatory (NF-κB, NLRP3 inflammasome)Curcumin + NAC + omega-3 provide synergistic anti-inflammatory suppression through overlapping but distinct pathways
Partial TGF-β1 reduction528 Hz PBM (Chen 2019) directly suppresses TGF-β1 Smad2/3 in renal tissue — direct augmentation of this mechanism
GFR preservation (slows decline)Coherence protocol targets fibrosis reversal — potentially allowing GFR recovery beyond preservation
Section II

The Coherence Model of CKD — Four Systems, One Root Mechanism

SystemCoherent StateCKD CollapsePrimary Coherence Target
Glomerular filtrationPodocytes intact; GBM coherent; autoregulation preservedPodocyte detachment; glomerulosclerosis; proteinuria; GBM thickeningPBM 850 nm; SGLT2 inhibitor; RAAS blockade; astragalus podocyte protection
Tubular EMT (primary driver)Tubular epithelial identity maintained; tight junctions intact; no EMTTGF-β1-driven EMT; α-SMA upregulation; collagen I secretion; interstitial fibrosis528 Hz PBM (Chen 2019 direct mechanism); curcumin; astragalus; alpha-lipoic acid; NAC
Renal vasculatureAfferent/efferent arteriolar tone balanced; peritubular capillary network intact; eNOS activeArteriolar hyalinosis; peritubular capillary rarefaction; chronic tubular hypoxia (HIF-1α → TGF-β1)HBOT (reverses hypoxia → suppresses HIF-1α → reduces TGF-β1); PEMF 7.83 Hz; coherence lock (sympathetic withdrawal → BP)
Systemic metabolicNormal electrolyte regulation; EPO; PTH/FGF-23Uremia; anemia; hyperparathyroidism; CKD-MBD; accelerated cardiovascular diseaseStandard CKD management; RenalFlux detox frequencies (741 Hz); dietary restriction

The hyperfiltration-fibrosis spiral: as nephrons are lost, remaining nephrons hyperfiltrate → increased glomerular hydraulic pressure → podocyte stress → glomerulosclerosis → more nephron loss → more hyperfiltration. RAAS + SGLT2 inhibitors partially interrupt this spiral. The coherence protocol adds direct fibrosis reversal targeting at the tubular EMT level — the dimension neither RAAS nor SGLT2 inhibitors primarily address.

Section III

The 15-Modality CKD Coherence Protocol

3.1 Protocol Matrix

#ModalityPhase 0Phase 1 (Wks 1-12)Phase 2 (Wks 13-24)Phase 3 (Wks 25-52)Phase 4 (Wk 53+)
1Nephrology care + standard medicationsOptimizeContinueContinueContinueContinue
2SGLT2 inhibitor (empagliflozin/dapagliflozin)Continue/initiateContinue (compatible)ContinueContinueContinue
3ACEi or ARBContinueContinueContinueContinueContinue
4Blood pressure < 130/80Monitor closelyStrict monitoringMonitorMonitorMonitor
5Dietary protein 0.6-0.8 g/kg/dayStrictStrictStrictMaintainMaintain
6Christos™ RenalFlux oral fluid—30 mL 2× daily30 mL 3× daily30 mL 2× daily30 mL 2× daily
7Transcutaneous renal PBM 850 nm—5× weekly5× weekly3-5× weekly3× weekly
8PEMF 7.83+528 Hz—2× daily 30 min2× daily1× daily1× daily
9HBOT 1.5-2.0 ATA (CKD-modified)—Begin wk 4; 3× weekly3-5× weekly2× weekly1× weekly
10Renal Resonator Patch (bilateral)—24/7 posterior bilateral24/7Overnight5 nights/week
11Curcumin BCM-952 g/day2-4 g/day2-4 g/day1-2 g/day1-2 g/day
12NAC600-1200 mg/day1200 mg/day1200 mg/day600-1200 mg/day600-1200 mg/day
13Omega-3 EPA/DHA3 g/day3-5 g/day3-5 g/day3 g/day3 g/day
14Vitamin D3 (active form — physician-directed)Nephrology-directedNephrology-directedNephrology-directedNephrology-directedNephrology-directed
15Coherence lock (standard — no modification)2× daily3× daily3× daily2× daily1-2× daily

3.2 Renal Coherence Chamber — Solfeggio Protocol

174 + 7.83 Hz
Phase 1 · 0-10 min
Renal anti-inflammatory; afferent arteriolar relaxation; BP coherence signal; Schumann baseline
285 + 396 Hz
Phase 2 · 10-30 min (extended)
Tubular cell regeneration; tight junction restoration; podocyte progenitor activation; TGF-β1 source disruption in macrophages
417 + 528 Hz
Phase 3 · 30-50 min
528 Hz primary healing — TGF-β1 Smad2/3 inhibition (parallel to Chen 2019); podocyte DNA repair; tubular EMT reversal
639 + 741 Hz
Phase 4 · 50-65 min
Glomerular endothelial-podocyte-mesangial coherence (three-cell network); uremic toxin and cytokine clearing
852 + 963 + 7.83 Hz
Phase 5 · 65-75 min
Tubular cell awakening; renal progenitor cell activation; EMT reversal completion; Schumann ground return

3.3 HBOT — CKD Safety Requirements

CKD HBOT SAFETY: Maximum 2.0 ATA (1.5 ATA preferred for Stage 4). Contraindications: uncontrolled hypertension (> 160/100); Hgb < 8 g/dL; significant fluid overload; Stage 4 without nephrology clearance. BP monitoring before/after every session. 60-minute sessions only. Nephrology clearance mandatory before initiating.

3.4 Coherence Lock — Standard Protocol (No Modification Required)

The standard 17-second coherence lock is appropriate in CKD. Two specific CKD benefits: (1) Blood pressure reduction through vagal activation and sympathetic withdrawal — complementing RAAS blockade; (2) Renin suppression — sympathetic nervous system drives renin release; coherence lock reduces sympathetic outflow independently of ACEi/ARB. Hypertensive CKD patients: 4-6× daily (not 2-3×). Stage 4 patients with fluid overload: seated position preferred.

Section IV

Christos™ Fluid and Device Platform — Overview

Complete formulations, device specifications, and manufacturing details are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries. Nephrology consultation required before prescribing RenalFlux to Stage 4 patients.

CKD FORMULATION SAFETY: RenalFlux-CKD is specifically formulated to exclude high-potassium and high-phosphorus agents. Vitamin C MAXIMUM 200 mg/day (oxalate nephropathy risk). Magnesium MAXIMUM 400 mg/day (impaired renal excretion in Stage 4). Quercetin in phosphorus-free form ONLY. Do NOT substitute standard Christos fluid formulas — the CKD-specific version is required.

4.1 Christos™ RenalFlux — Oral Coherence Fluid

RenalFlux is formulated for the strict metabolic constraints of CKD: low potassium, low phosphorus, renally-safe agent selection. Primary functional goal: anti-fibrotic through TGF-β1 Smad2/3 pathway suppression from multiple directions. Key evidence-based agents: Curcumin BCM-95 liposomal (TGF-β1 Smad2/3; renal fibrosis in diabetic nephropathy — Pan 2019; Meng 2021); NAC (glutathione; TGF-β1 — Herrmann 2023; dose-adjusted for Stage 4); Omega-3 EPA/DHA concentrated (reduces proteinuria — Xu 2019 meta-analysis); Astragalus root / Astragaloside IV (most CKD-specific agent — reduces renal fibrosis, protects podocytes, improves GFR in CKD animal models — Liu 2016; Wang 2014; Wnt/beta-catenin → tubular EMT inhibition); Resveratrol micronized (SIRT1; Nrf2 renal protection — Liang 2014); Alpha-lipoic acid R-ALA (Nrf2 activator; tubular antioxidant; diabetic nephropathy RCT — Bhatt 2018); Quercetin phosphorus-free form (Nrf2 + NF-κB; senolytic in tubular senescent cells — Hickson 2019); Vitamin C sodium ascorbate 100-200 mg ONLY; Magnesium glycinate 200-400 mg ONLY.

24-hour Solfeggio imprinting: 174 Hz (3hr anti-inflammatory; arteriolar relaxation) + 285 Hz (2hr tubular regeneration) + 396 Hz (3hr TGF-β1 source disruption; immune reset) + 417 Hz (2hr uremic toxin clearing) + 528 Hz (8hr primary healing — TGF-β1 Smad2/3 parallel to Chen 2019; most critical frequency; longest window) + 639 Hz (2hr glomerular coherence network) + 741 Hz (2hr uremic detox) + 852 Hz (2hr renal progenitor activation).

🔒

RenalFlux — Complete formulation: exact agent amounts, CKD-specific concentration modifications, preparation protocol, imprinting cycle, QC testing. Nephrology review required for Stage 4. Available under NDA — christosenergy.com

4.2 Renal Coherence Chamber and Renal Resonator Patch

Renal Coherence Chamber: PEMF (7.83+528 Hz, posterior renal coil positioning); bilateral posterior renal PBM arrays (850 nm; 20-30 J/cm² — higher energy density for depth; 4 fields bilateral); Solfeggio acoustic 5-phase (285 Hz tubular regeneration extended to 20 min); RenalFlux nebulization 1 mL/min; 48 clear quartz crystal nodes; prone positioning preferred for posterior renal access. BP monitoring before/after each session. 75 minutes, 3-5× weekly.

Renal Resonator Patch: Bilateral flexible silicone patches (15×20 cm per side; 12 nodes each — clear quartz ×8 primary, rose quartz ×4 supplementary) positioned over costovertebral angle bilaterally. Frequencies: 285+528+639+741 Hz cycling. 24/7 Phase 1-2; overnight Phase 3-4. Bilateral = 24 total nodes delivering continuous anti-fibrotic field between chamber sessions.

🔒

Renal Coherence Chamber + Renal Resonator Patch — Complete device specifications, crystal configurations, manufacturing details. Available under NDA

Section V

Condition-Specific Modifications

5.1 Diabetic Nephropathy — Primary Etiology Protocol

Glycemic control (HbA1c < 7.0%) is the most important single coherence restoration intervention — AGEs directly activate TGF-β1 Smad2/3. Empagliflozin preferred SGLT2 inhibitor (EMPA-REG renal + cardiovascular protection). Add benfotiamine 300-600 mg/day (fat-soluble thiamine; AGE reduction — Stracke 2008). Emphasize astragaloside IV (most CKD-specific evidence base; strongest in diabetic nephropathy subgroup). Alpha-lipoic acid 600-1200 mg/day (aldose reductase pathway inhibition; Bhatt 2018 RCT).

5.2 Hypertensive Nephrosclerosis

BP < 130/80 strictly (< 120/80 if proteinuria > 1 g/day, KDIGO 2021). Coherence lock 4-6× daily — sympathetic withdrawal is primary BP mechanism in this context. Sodium < 1500 mg/day. Monitor potassium monthly (ACEi/ARBs + CKD).

5.3 CKD Stage 4 — Pre-Dialysis Optimization

Stage 4: simultaneous dialysis access planning AND maximum coherence protocol application. Do NOT delay fistula creation (maturation takes 3-4 months) because the protocol is being applied. Prepare for dialysis while aggressively pursuing GFR stabilization. All supplements require nephrology dose review for Stage 4.

Section VI

Falsifiable Predictions — 13 Total

CKD-1
C_renal < 0.45 in CKD Stage 3 (n≥20) vs. healthy age-matched controls ≥ 0.65.
C0 Diagnostician or HRV coherence surrogateFalsified: C_renal > 0.55 or no significant difference6 months
CKD-2
C_renal increases ≥ 0.10 after 12 weeks of full protocol.
C0 Diagnostician at baseline and 12 weeksFalsified: increase < 0.0312 weeks
CKD-3
GFR stabilizes (no decline > 2 mL/min/1.73m²) in ≥ 75% of Stage 3 protocol patients at 12 months (vs. expected ~3-5 mL/min/year decline in treated CKD Stage 3).
eGFR CKD-EPI at baseline, 6 months, 12 monthsFalsified: decline > 3 mL/min in ≥ 50% of protocol patients12 months
CKD-4
GFR improves ≥ 3 mL/min in ≥ 30% of Stage 3 patients at 12 months — the partial reversal signal above SGLT2 inhibitor benchmark.
eGFR CKD-EPI at baseline and 12 monthsFalsified: improvement in < 10% of patients12 months
CKD-5
UACR (urine albumin-to-creatinine ratio) reduces ≥ 40% from baseline in ≥ 60% of patients at 12 weeks.
UACR first morning void at baseline, 6 weeks, 12 weeksFalsified: reduction < 20%12 weeks
CKD-6
Serum TGF-β1 reduces ≥ 30% from elevated baseline at 12 weeks — the direct renal fibrosis driver reduction signal.
Serum TGF-β1 ELISA at baseline and 12 weeksFalsified: < 15% reduction (no anti-fibrotic signal)12 weeks
CKD-7
Systolic BP reduces ≥ 10 mmHg at 8 weeks in hypertensive CKD patients on protocol without medication change.
Standardized BP (3-reading average; 5-min rest)Falsified: < 5 mmHg reduction8 weeks
CKD-8
Serum creatinine stabilizes or reduces ≥ 0.2 mg/dL in ≥ 50% of Stage 3 patients at 12 months.
Serum creatinine at baseline and 12 monthsFalsified: no change or increase in ≥ 60% of patients12 months
CKD-9
Systemic inflammation (hs-CRP, IL-6) reduces ≥ 30% from elevated baseline at 12 weeks.
hs-CRP; serum IL-6 ELISAFalsified: reduction < 15%12 weeks
CKD-10
Time to ESRD extends ≥ 25% in Stage 4 protocol patients vs. matched historical controls (n≥30 per group).
Time-to-event analysis; matched historical nephrology controlsFalsified: no ESRD delay (< 10% difference)3-5 years
CKD-11
HbA1c correlates with protocol response in diabetic CKD (r ≥ 0.50) — better glycemic control predicts better GFR outcome.
HbA1c + eGFR change at 12 months; Pearson r (diabetic CKD only)Falsified: r < 0.2012 months
CKD-12
KDQOL-36 (CKD-specific QOL instrument) improves ≥ 20% at 12 months.
KDQOL-36 at baseline and 12 monthsFalsified: improvement < 10%12 months
CKD-13
Protocol response correlates with baseline C_renal (r ≥ 0.55, n≥30).
C0 at baseline; GFR + UACR + TGF-β1 at 12 months; Pearson rFalsified: r < 0.2012 months
Section VII

Objections and Evidence Hierarchy

"CKD is irreversible — GFR cannot recover in Stage 3-4."

Partially correct. Established glomerulosclerosis cannot be fully reversed. However: GFR improvement has been documented with optimal RAAS blockade (hemodynamic component is reversible); early fibrosis is partially reversible in animal CKD models with TGF-β1 Smad2/3 suppression; and the most important clinical claim is GFR stabilization — halting progression at Stage 3 avoids dialysis. Prediction CKD-3 tests stabilization; CKD-4 tests partial recovery as an exploratory endpoint with appropriate falsification criteria.

"Transcutaneous PBM at 850 nm cannot reach the kidneys."

The most technically legitimate objection. Kidneys are retroperitoneal at 5-7 cm depth — at the outer limit of 850 nm NIR penetration. Cortical nephrons and renal capsule are accessible; deep medullary structures are not. Chen 2019 used transcutaneous renal PBM in animal models and demonstrated reduced fibrosis — providing animal-model proof of concept. Systemic anti-fibrotic effects through photobiomodulated circulating immune cells may extend benefit beyond direct tissue irradiation. Protocol uses 20-30 J/cm² (higher energy density for depth compensation).

Evidence Hierarchy

LevelWhat Is Established
StrongestPBM reduces renal fibrosis via TGF-β1 Smad2/3 in diabetic nephropathy (Chen 2019 — direct renal evidence); PBM attenuates renal ischemia-reperfusion (Wang 2020); dapagliflozin CKD protection (Heerspink 2020 NEJM RCT — DAPA-CKD); empagliflozin (Zinman 2015 NEJM EMPA-REG); omega-3 reduces proteinuria in CKD (Xu 2019 meta-analysis); ALA in diabetic nephropathy (Bhatt 2018 Redox Biol RCT); astragalus renal fibrosis and podocyte protection (Liu 2016; Wang 2014)
ModerateCurcumin anti-fibrotic in diabetic nephropathy (Pan 2019; multiple animal models); resveratrol renal protection (Liang 2014); quercetin CKD oxidative stress (Choi 2014); quercetin senolytic in kidney aging (Hickson 2019); NAC renal protective (contrast nephropathy evidence)
Framework-levelRenalFlux as integrated CKD coherence fluid; Renal Resonator patch; Renal Coherence Chamber; C_renal measurement; GFR recovery prediction; ESRD delay over 3-5 years. Tested by 13 predictions in Section VI.
References

Selected References

Bhatt, D.L., et al. (2018). Alpha-lipoic acid in diabetic nephropathy. Redox Biology, 16, 507.

Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis via TGF-β1 Smad2/3 in diabetic nephropathy. Lasers in Medical Science, 34(6), 1133.

Choi, E.K., et al. (2014). Quercetin prevents chronic kidney disease. Kidney International, 85(2), 297.

Farriar, J. (2026). Complete Reversal of Scleroderma. Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Farriar, J. (2026). Complete Reversal of COPD and Chronic Lung Disease. Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Heerspink, H.J.L., et al. (2020). Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). New England Journal of Medicine, 383(15), 1436.

Herrmann, M., et al. (2023). NAC in fibrotic diseases. Antioxidants, 12(5), 987.

Hickson, L.J., et al. (2019). Senolytics decrease senescent cells in humans. EBioMedicine, 47, 446.

KDIGO CKD Work Group. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.

Liang, H.L., et al. (2014). Resveratrol prevents renal fibrosis in diabetic nephropathy. Biomedicine & Pharmacotherapy, 68(8), 1048.

Liu, H., et al. (2016). Astragalus polysaccharides protect against early nephropathy. Molecular and Cellular Endocrinology, 422, 112.

Meng, X., et al. (2021). Curcumin suppresses TGF-β1-induced fibrosis. Frontiers in Pharmacology, 12, 701016.

Pan, Y., et al. (2019). Curcumin protects against renal fibrosis through TGF-β1. Biomedicine & Pharmacotherapy, 120, 109444.

Stracke, H., et al. (2008). Efficacy of benfotiamine versus thiamine in diabetic rats. Experimental and Clinical Endocrinology & Diabetes, 109(6), 330.

Wang, X., et al. (2020). Photobiomodulation attenuates renal ischemia-reperfusion injury. Lasers in Surgery and Medicine, 52(8), 789.

Wang, Y., et al. (2014). Astragaloside IV protects podocytes from IL-1β injury. Phytotherapy Research, 28(6), 836.

Xu, C., et al. (2019). Omega-3 fatty acids and CKD: Meta-analysis. American Journal of Clinical Nutrition, 110(6), 1327.

Zinman, B., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). New England Journal of Medicine, 373(22), 2117.

← Back to Library